UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| ||
| (Address of principal executive offices) | (Zip Code) |
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 2.02 | Results of Operations and Financial Condition. |
On May 13, 2026, Xtant Medical Holdings, Inc. (the “Company”) announced its financial results for the three months ended March 31, 2026. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in Item 2.02 of this report (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any registration statement or other document filed by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such a filing.
To supplement its consolidated financial statements prepared in accordance with United States generally accepted accounting principles (“GAAP”), the Company uses certain non-GAAP financial measures, such as non-GAAP adjusted EBITDA, which are included in the press release furnished as Exhibit 99.1 to this report. The Company defines non-GAAP adjusted EBITDA as net income (loss) from operations before depreciation and amortization expense; interest expense, net; and tax benefit (expense), and as further adjusted to add back in or exclude, non-cash compensation, divestiture/acquisition-related income and expenses, acquisition-related fair value adjustments, unrealized foreign currency translation loss or gain, and separation-related expenses, in each case as applicable.
The Company uses non-GAAP adjusted EBITDA in making operating decisions because it believes this measure provides meaningful supplemental information regarding its core operational performance. Additionally, this measure gives the Company a better understanding of how it should invest in sales and marketing and research and development activities and how it should allocate resources to both ongoing and prospective business initiatives. The Company also uses non-GAAP adjusted EBITDA to help make budgeting and spending decisions, for example, among sales and marketing expenses, general and administrative expenses, and research and development expenses. Additionally, the Company believes its use of non-GAAP adjusted EBITDA facilitates management’s internal comparisons to historical operating results by factoring out potential differences caused by charges not related to its regular, ongoing business, including, without limitation, non-cash charges and certain large and unpredictable charges or gains.
As described above, the Company excludes the effect of the following items from its non-GAAP adjusted EBITDA for the following reasons:
Non-cash compensation. The Company excludes non-cash compensation, which is a non-cash charge related to equity awards granted by the Company. Although non-cash compensation is a recurring charge to the Company’s operations, management has excluded it because it relies on valuations based on future events, such as the market price of the Company’s common stock, that are difficult to predict and are affected by market factors that are largely not within the control of the Company. Thus, management believes that excluding non-cash compensation facilitates comparisons of the Company’s operational performance in different periods, as well as with similarly determined non-GAAP financial measures of comparable companies.
Divestiture/acquisition-related expenses and income related to transition services agreements. The Company excludes expenses and income directly related to the Company’s divestitures and acquisitions and subsequent integration and transition activities from non-GAAP adjusted EBITDA primarily because such expenses and income are not reflective of the Company’s ongoing operating results and are not used by management to assess the core profitability of the Company’s business operations. These expenses and income include legal and accounting fees, as well fees charged by the Company in connection with post-divestiture services performed for divested operations. These expenses and income are not considered normal, recurring, cash operating expenses/income necessary to operate the Company’s business. The Company further believes that excluding these expenses and income from its non-GAAP results is useful to investors in that it allows for period-over-period comparability.
Acquisition-related fair value adjustments. The Company excludes acquisition-related fair value adjustments from non-GAAP adjusted EBITDA primarily because such adjustments are not reflective of the Company’s ongoing operating results and are not used by management to assess the core profitability of the Company’s business operations. The Company further believes that excluding this item from its non-GAAP results is useful to investors in that it allows for period-over-period comparability.
Unrealized foreign currency translation gain or loss. The Company excludes unrealized foreign currency translation gain or loss, as applicable, from non-GAAP adjusted EBITDA primarily because such gain or loss is not reflective of the Company’s ongoing operating results and is not used by management to assess the core profitability of the Company’s business operations. The Company further believes that excluding this item from its non-GAAP results is useful to investors in that it allows for period-over-period comparability.
Separation-related expenses. The Company excludes separation-related expenses primarily because such expenses are not reflective of the Company’s ongoing operating results and are not used by management to assess the core profitability of the Company’s business operations. The Company further believes that excluding this item from its non-GAAP results is useful to investors in that it allows for period over-period comparability.
Non-GAAP adjusted EBITDA is reconciled to net income (loss), the most directly comparable GAAP measure in the press release. The Company also presents in the press release EBITDA as a percentage of total revenue and adjusted EBITDA as a percentage of total revenue and reconciles these two non-GAAP measures in the press release to net income (loss) as a percentage of total revenue.
Non-GAAP financial measures are not in accordance with, or an alternative for, GAAP measures and may be different from non-GAAP financial measures used by other companies. In addition, non-GAAP financial measures are not based on any comprehensive or standard set of accounting rules or principles. Accordingly, the calculation of the Company’s non-GAAP financial measures may differ from the definitions of other companies using the same or similar names, limiting, to some extent, the usefulness of such measures for comparison purposes. Non-GAAP financial measures have limitations in that they do not reflect all of the amounts associated with the Company’s financial results as determined in accordance with GAAP. Non-GAAP financial measures should only be used to evaluate the Company’s financial results in conjunction with the corresponding GAAP measures. Accordingly, the Company qualifies its use of non-GAAP financial information in a statement when non-GAAP financial information is presented.
| Item 8.01 | Other Events. |
On May 13, 2026, the Company announced August 7, 2026 as the date of the Company’s 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”). The exact time and location of the 2026 Annual Meeting will be specified in the Company’s proxy statement for the 2026 Annual Meeting, which it anticipates will be printed on or about June 11, 2026 and sent or made available to stockholders commencing on or about June 12, 2026.
Since the date of the Company’s 2026 Annual Meeting has changed by more than 30 days from the date of last year’s Annual Meeting of Stockholders, stockholders who, in accordance with Rule 14a-8 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), wish to present proposals for inclusion in the proxy materials relating to the 2026 Annual Meeting must submit their proposals so that they are received by the Company at its principal executive offices no later than the close of business on May 23, 2026, which the Company believes is a reasonable time before it prints and mails its proxy materials. The proposals must satisfy the requirements of the proxy rules promulgated by the Securities and Exchange Commission (the “SEC”) and as the rules of the SEC make clear, simply submitting a proposal does not guarantee that it will be included.
The Company’s Third Amended and Restated Bylaws (the “Bylaws”) provide for an advance notice procedure with regard to nominations of persons for election to the Board of Directors and stockholder proposals to be brought before an annual meeting. Pursuant to the terms of the Bylaws, any other stockholder proposals, including director nominations, to be presented at the 2026 Annual Meeting (other than a matter brought pursuant to SEC Rule 14a-8) are required to be given in writing to the Company’s Corporate Secretary and delivered to or mailed and received by the Company no later than the close of business on May 23, 2026, the 10th day following the date of this Current Report on Form 8-K announcing the date of the 2026 Annual Meeting, and must contain information specified in the Bylaws.
In addition, if applicable, stockholders who intend to solicit proxies in support of director nominees other than the Company’s nominees at the 2026 Annual Meeting must comply with the “universal proxy rules,” Rule 14a-19 promulgated under the Exchange Act, as required by and in addition to the Bylaws, including providing written notice on a timely basis no later than June 9, 2026, which is 60 days prior the date of the 2026 Annual Meeting, and providing certain information required by Rule 14a-19 under the Exchange Act (including a statement that such stockholder intends to solicit the holders of shares representing at least 67% of the voting power of the Company’s shares entitled to vote on the election of directors in support of director nominees other than the Company’s nominees) to the Company.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits.
| Exhibit No. | Description | |
| 99.1 | Press Release of Xtant Medical Holdings, Inc. dated May 13, 2026 entitled “Xtant Medical Reports First Quarter 2026 Financial Results” (furnished herewith) | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| XTANT MEDICAL HOLDINGS, INC. | ||
| By: | /s/ Scott C. Neils | |
| Scott C. Neils | ||
| Chief Financial Officer | ||
Date: May 13, 2026
Exhibit 99.1
Xtant Medical Reports First Quarter 2026 Financial Results
Raises full-year 2026 revenue guidance to a range of $101-$105 million
Significantly strengthens balance sheet
Enters into exclusive U.S. distribution agreement for Dilon Technologies’ HEMOBLAST® Bellows product for high-performance hemostasis; hires Dilon’s U.S. sales team
BELGRADE, Mont., May 13, 2026 — Xtant Medical Holdings, Inc. (NYSE American: XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions, today reported financial and operating results for the first quarter ended March 31, 2026.
First Quarter 2026 Financial Highlights
| ● | Generated total revenue of $20.9 million for the first quarter of 2026, as compared to $32.9 million for the first quarter of 2025. The decline in revenue relates primarily to the sale of assets and businesses to Companion Spine in December 2025 as well as 2025 license revenue that will not repeat in 2026. | |
| ● | Reduced total indebtedness by $13.3 million in the first quarter of 2026, including a $10.4 million reduction in net amounts outstanding under the Company’s revolving line of credit, and a $2.8 million reduction in its term loan balance. | |
| ● | Increased full-year 2026 revenue guidance to a range of $101 million to $105 million, from $95 million to $99 million previously, to reflect anticipated incremental revenue contribution from Dilon’s HEMOBLAST® Bellows hemostatic product that was licensed in April 2026. |
First Quarter 2026 and Recent Business Highlights
| ● | Announced an exclusive U.S. distribution agreement with privately held Dilon Technologies whereby Xtant has acquired the exclusive U.S. commercial rights to Dilon’s HEMOBLAST® Bellows product for high-performance hemostasis following certain surgical procedures. As part of the transaction, Xtant has hired Dilon’s approximately 20-person U.S. sales team. | |
| ● | Launched Trivium™ Shaped, an extension of its Trivium line of premium, next-generation demineralized bone matrix allograft for bone grafting procedures. Trivium™ Shaped is available in pre-shaped configurations designed to support handling, preparation, and placement across a range of surgical applications. | |
| ● | Received the final $10.7 million due from Companion Spine in March, finalizing the previously announced sale of Xtant’s non-core Coflex®/CoFix assets and its international hardware business to Companion, and resulting in a total cash purchase price of $21.4 million. |
Sean Browne, President and CEO of Xtant Medical, stated, “The first quarter of 2026 and subsequent period were pivotal for Xtant. Proceeds from the Companion Spine transaction allowed us to strengthen our balance sheet while the HEMOBLAST® Bellows distribution agreement announced in April expanded our addressable market into the multi-billion-dollar hemostatics category. We are particularly encouraged by the potential commercial synergies to be realized following the integration of Dilon’s 21-person field sales force into our own organization, positioning us to drive topline growth and margin expansion this year and beyond. These developments, together with recent product launches, position us to best serve the needs of surgeons and patients alike with our comprehensive biologics product portfolio.”
First Quarter 2026 Financial Results
Revenue for the first quarter of 2026 was $20.9 million, compared to $32.9 million for the same period in 2025. The year-over-year decline is primarily due to the sale of the company’s Coflex/CoFix assets and international hardware business to Companion Spine in December of 2025, as well as license revenue from Xtant’s Q-code and amniotic membrane agreements in the first quarter of 2025 that did not repeat in the first quarter of 2026 due to changes in the reimbursement environment.
Gross margin for the first quarter of 2026 was 57.3%, compared to 61.5% for the same period in 2025. The decrease was primarily due to the cessation of Q-code high-margin license revenue from the amniotic membrane agreements that ceased at the end of 2025.
Operating expenses for the first quarter of 2026 totaled $14.9 million, compared to $19.2 million for the first quarter of 2025. The decrease was primarily due to the company’s sale of its Coflex/CoFix assets and international hardware business to Companion Spine in December 2025.
First quarter 2026 net loss was $3.1 million, compared to net income of $58,000 for the first quarter of 2025.
Non-GAAP adjusted EBITDA loss for the first quarter of 2026 totaled $1.6 million, compared to positive adjusted EBITDA of $3.0 million for the same period in 2025.
The Company defines adjusted EBITDA as net income/loss from operations before depreciation, amortization and interest income/expense and provision for income tax/benefit, and as further adjusted to add back in or exclude, as applicable, separation-related expenses, non-cash compensation, disposition/acquisition-related income and expenses, acquisition-related fair value adjustments, and unrealized foreign currency translation gain or loss. A calculation and reconciliation of adjusted EBITDA to net income (loss) can be found in the attached financial tables.
As of March 31, 2026, the Company had $12.2 million of cash and cash equivalents, total indebtedness of $12.2 million, and availability under its revolving credit facility of $11.8 million compared to $17.3 million of cash and cash equivalents, total indebtedness of $25.4 million, and availability under its revolving credit facility of $3.8 million as of December 31, 2025. The reduction in total indebtedness was due primarily to the term loan payment of $2.8 million from some of the February 2026 proceeds from Companion Spine and net repayments of $10.4 million on the revolving credit facility from cash and cash equivalents, and the resulting increase in availability under the revolving credit agreement is due to an effort to reduce interest expense by minimizing the outstanding balance on the Company’s revolving credit facility.
2026 Financial Guidance
The Company is today increasing its full-year 2026 revenue guidance to a range of $101 million to $105 million, from $95 million to $99 million previously, to reflect the recently announced exclusive license agreement with Dilon Technologies and anticipated incremental revenue contribution from Dilon’s HEMOBLAST® Bellows.
Conference Call
Xtant Medical will host a webcast and conference call to discuss its first quarter 2026 financial and operating results at 8:30 am ET today, May 13, 2026.
To access the webcast: https://www.webcaster5.com/Webcast/Page/3039/53872
To access the conference call, dial 888-506-0062 (US) or 973-528-0011 (International) and reference Participant Access Code 638297.
A replay of the call will be available on the Investor section of the Company’s website at www.xtantmedical.com for a period of one year.
About Xtant Medical Holdings, Inc.
Xtant Medical’s mission of honoring the gift of donation so that our patients can live as full and complete a life as possible, is the driving force behind our company. Xtant Medical Holdings, Inc. (www.xtantmedical.com) is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics serving the chronic and surgical wound care and sports medicine markets, as well as spinal implant systems. Xtant people are dedicated and talented, operating with the highest integrity to serve our customers.
The symbols ™ and ® denote trademarks and registered trademarks of Xtant Medical Holdings, Inc. or its affiliates, registered as indicated in the United States, and in other countries. All other trademarks and trade names referred to in this release are the property of their respective owners.
Non-GAAP Financial Measures
To supplement the Company’s consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles (GAAP), the Company uses certain non-GAAP financial measures in this release, including adjusted EBITDA, adjusted EBITDA as a percentage of total revenue. Reconciliations of the non-GAAP financial measures used in this release to the most comparable GAAP measures for the respective periods can be found in this release or tables later in this release. The Company’s management believes that the presentation of these measures provides useful information to investors. These measures may assist investors in evaluating the Company’s operations, period over period. Management uses the non-GAAP measures in this release internally for evaluation of the performance of the business, including the allocation of resources. Investors should consider non-GAAP financial measures only as a supplement to, not as a substitute for or as superior to, measures of financial performance prepared in accordance with GAAP.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as “intends,” ‘‘expects,’’ ‘‘anticipates,’’ ‘‘plans,’’ ‘‘believes,’’ ‘‘estimates,’’ “continue,” “future,” ‘‘will,’’ “potential,” “going forward,” “guidance,” similar expressions or the negative thereof, and the use of future dates. Forward-looking statements in this release include the Company’s full year 2026 revenue guidance, including anticipated incremental revenue contribution from Dilon’s HEMOBLAST® Bellows hemostatic product. The Company cautions that its forward-looking statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others: the Company’s future operating results, financial performance and need for additional capital; the Company’s ability to drive topline growth and margin expansion this year and beyond; the success of the distribution arrangement and the HEMOBLAST® Bellows product, including future U.S. sales and the additional U.S. sales personnel and their impact on the Company’s business and operating results; the possibility that the distribution agreement may be terminated by either party; the effect of the distribution agreement on the Company’s business, including its relationships with other distributors, independent sales representatives and personnel, and its business and operating results; the success of the Company’s expanded field sales force to improve the Company’s reach and leverage its contract portfolio and independent agent network; the Company’s ability to become operationally self-sustaining and less reliant on third-party manufacturers and suppliers; risks associated with acquisitions and dispositions; its ability to implement successfully its future growth initiatives and risks associated therewith; possible future impairment charges to long-lived assets and goodwill and write-downs of excess and obsolete inventory; its ability to continue to innovate, develop and introduce new products and the success of those products; its ability to remain competitive; its ability to engage and retain new and existing independent distributors and agents and qualified sales and other personnel and its dependence on key independent agents for a significant portion of its revenue; the effect of inflation, elevated interest rates and other recessionary factors and supply chain disruptions; the effect of product sales mix changes on its financial results; the effect of government and third-party coverage and reimbursement for its products; its ability to obtain and maintain regulatory approvals and comply with government regulations; the effect of product liability claims and other litigation to which the Company may be subject; the effect of product recalls and defects; its ability to license intellectual property on commercially reasonable terms and to maintain any such licenses and its ability to obtain and protect its intellectual property and proprietary rights and operate without infringing the rights of others; its ability to service its debt, comply with debt covenants, and access additional indebtedness or financing on favorable terms or at all, if and when needed; and other factors described in its Annual Report on Form 10-K for the year ended December 31, 2025 to be filed with the Securities and Exchange Commission (SEC) on March 30, 2026 and subsequent SEC reports, including its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2026 to be filed with the SEC on May 13, 2026. Investors are encouraged to read the Company’s filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The Company undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by this cautionary statement.
Investor Relations Contact:
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com
-OR-
Rob Windsor
LifeSci Advisors
rwindsor@lifescipartners.com
– Tables Follow –
XTANT MEDICAL HOLDINGS, INC.
Consolidated Balance Sheets
(In thousands, except number of shares and par value)
| As of March 31, 2026 | As of December 31, 2025 | |||||||
| (Unaudited) | ||||||||
| ASSETS | ||||||||
| Current Assets: | ||||||||
| Cash and cash equivalents | $ | 12,137 | $ | 17,053 | ||||
| Restricted cash | 20 | 275 | ||||||
| Trade accounts receivable, net of allowance for credit losses of $2,115 and $2,165, respectively | 17,179 | 17,803 | ||||||
| Inventories | 31,881 | 30,263 | ||||||
| Note receivable | — | 10,462 | ||||||
| Prepaid and other current assets | 1,404 | 2,389 | ||||||
| Total current assets | 62,621 | 78,245 | ||||||
| Property and equipment, net | 5,854 | 6,202 | ||||||
| Right-of-use asset, net | 3,045 | 3,192 | ||||||
| Goodwill | 6,074 | 6,074 | ||||||
| Intangible assets, net | 275 | 299 | ||||||
| Other assets | 131 | 133 | ||||||
| Total Assets | $ | 78,000 | $ | 94,145 | ||||
| LIABILITIES & STOCKHOLDERS’ EQUITY | ||||||||
| Current Liabilities: | ||||||||
| Accounts payable | $ | 5,485 | $ | 3,844 | ||||
| Accrued liabilities | 8,475 | 10,626 | ||||||
| Current portion of long-term debt | 3,720 | 3,500 | ||||||
| Current portion of lease liability | 617 | 622 | ||||||
| Current portion of finance lease obligations | 35 | 35 | ||||||
| Line of credit | 441 | 10,857 | ||||||
| Total current liabilities | 18,773 | 29,484 | ||||||
| Long-term Liabilities: | ||||||||
| Lease liability, less current portion | 2,525 | 2,665 | ||||||
| Finance lease obligation, less current portion | 3 | 12 | ||||||
| Long-term debt, plus premium and less issuance costs | 8,095 | 11,026 | ||||||
| Other liabilities | 5 | 5 | ||||||
| Total Liabilities | 29,401 | 43,192 | ||||||
| Commitments and Contingencies | ||||||||
| Stockholders’ Equity: | ||||||||
| Preferred stock, $0.000001 par value; 10,000,000 shares authorized; no shares issued and outstanding | — | — | ||||||
| Common stock, $0.000001 par value; 300,000,000 shares authorized; 140,068,260 shares issued and outstanding as of March 31, 2026 and 140,039,557 shares issued and outstanding as of December 31, 2025 | — | — | ||||||
| Additional paid-in capital | 306,175 | 305,439 | ||||||
| Accumulated other comprehensive loss | (1 | ) | — | |||||
| Accumulated deficit | (257,575 | ) | (254,486 | ) | ||||
| Total Stockholders’ Equity | 48,599 | 50,953 | ||||||
| Total Liabilities & Stockholders’ Equity | $ | 78,000 | $ | 94,145 | ||||
XTANT MEDICAL HOLDINGS, INC.
Consolidated Statements of Operations
(Unaudited, in thousands, except number of shares and per share amounts)
| Three Months Ended March 31, | ||||||||
| 2026 | 2025 | |||||||
| Revenue | ||||||||
| Product revenue | $ | 20,884 | $ | 29,284 | ||||
| License revenue | — | 3,620 | ||||||
| Total Revenue | 20,884 | 32,904 | ||||||
| Cost of sales | 8,913 | 12,661 | ||||||
| Gross Profit | 11,971 | 20,243 | ||||||
| Operating Expenses | ||||||||
| General and administrative | 6,273 | 7,533 | ||||||
| Sales and marketing | 8,186 | 11,204 | ||||||
| Research and development | 435 | 443 | ||||||
| Total Operating Expenses | 14,894 | 19,180 | ||||||
| (Loss) Income from Operations | (2,923 | ) | 1,063 | |||||
| Other Expense | ||||||||
| Interest expense | (599 | ) | (1,045 | ) | ||||
| Interest income | 219 | |||||||
| Unrealized foreign currency translation (loss) gain | (1 | ) | 24 | |||||
| Other income (expense) | 242 | (9 | ) | |||||
| Total Other Expense | (139 | ) | (1,030 | ) | ||||
| Net (Loss) Income from Operations Before Provision for Income Taxes | (3,062 | ) | 33 | |||||
| (Provision) Benefit for Income Taxes Current and Deferred | (27 | ) | 25 | |||||
| Net (Loss) Income | $ | (3,089 | ) | $ | 58 | |||
| Net (Loss) Income Per Share: | ||||||||
| Basic | $ | (0.02 | ) | $ | 0.00 | |||
| Dilutive | $ | (0.02 | ) | $ | 0.00 | |||
| Shares used in the computation: | ||||||||
| Basic | 140,058,787 | 139,068,831 | ||||||
| Dilutive | 140,058,787 | 143,335,114 | ||||||
XTANT MEDICAL HOLDINGS, INC.
Consolidated Statements of Cash Flows
(Unaudited, in thousands)
| Three Months Ended March 31, | ||||||||
| 2026 | 2025 | |||||||
| Operating activities: | ||||||||
| Net (loss) income | $ | (3,089 | ) | $ | 58 | |||
| Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities: | ||||||||
| Depreciation and amortization | 534 | 1,074 | ||||||
| Gain on sale of fixed assets | (14 | ) | (37 | ) | ||||
| Non-cash interest | 129 | 163 | ||||||
| Stock-based compensation | 746 | 758 | ||||||
| Provision for reserve on accounts receivable | 180 | 243 | ||||||
| Provision for excess and obsolete inventory | 922 | 541 | ||||||
| Other | 2 | (3 | ) | |||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable | 444 | (3,114 | ) | |||||
| Inventories | (1,611 | ) | (535 | ) | ||||
| Prepaid and other assets | 152 | 280 | ||||||
| Accounts payable | 1,641 | (890 | ) | |||||
| Accrued liabilities | (2,150 | ) | 2,740 | |||||
| Net cash (used in) provided by operating activities | (2,114 | ) | 1,278 | |||||
| Investing activities: | ||||||||
| Purchases of property and equipment | (194 | ) | (1,191 | ) | ||||
| Proceeds from sale of fixed assets | 46 | 48 | ||||||
| Proceeds from divestiture | 10,368 | — | ||||||
| Net cash provided by (used in) investing activities | 10,220 | (1,143 | ) | |||||
| Financing activities: | ||||||||
| Borrowings on line of credit | 1,630 | 25,158 | ||||||
| Repayments on line of credit | (12,045 | ) | (26,017 | ) | ||||
| Payments on long-term debt | (2,841 | ) | — | |||||
| Debt issuance costs | — | (34 | ) | |||||
| Payments on financing leases | (9 | ) | (17 | ) | ||||
| Payment of taxes from withholding of common stock on settlement of restricted stock units | (10 | ) | (9 | ) | ||||
| Net cash used in by financing activities | (13,275 | ) | (919 | ) | ||||
| Effect of exchange rate changes on cash and cash equivalents and restricted cash | (2 | ) | (2 | ) | ||||
| Net change in cash and cash equivalents and restricted cash | (5,171 | ) | (786 | ) | ||||
| Cash and cash equivalents and restricted cash at beginning of period | 17,328 | 6,221 | ||||||
| Cash and cash equivalents and restricted cash at end of period | $ | 12,157 | $ | 5,435 | ||||
| Reconciliation of cash and cash equivalents and restricted cash reported in the condensed consolidated balance sheets | ||||||||
| Cash and cash equivalents | $ | 12,137 | $ | 5,032 | ||||
| Restricted cash | 20 | 403 | ||||||
| Total cash and restricted cash reported in condensed consolidated balance sheets | $ | 12,157 | $ | 5,435 | ||||
XTANT MEDICAL HOLDINGS, INC.
CALCULATION OF NON-GAAP CONSOLIDATED EBITDA AND ADJUSTED EBITDA
(in thousands)
| Three Months Ended March 31, | ||||||||
| 2026 | 2025 | |||||||
| Net (Loss) Income | $ | (3,089 | ) | $ | 58 | |||
| Depreciation and amortization | 534 | 1,074 | ||||||
| Interest expense, net | 380 | 1,045 | ||||||
| Tax expense | 27 | (25 | ) | |||||
| Non-GAAP EBITDA | (2,148 | ) | 2,152 | |||||
| Net (Loss) Income/Total Revenue | (14.8 | )% | 0.2 | % | ||||
| Non-GAAP EBITDA/Total Revenue | (10.3 | )% | 6.5 | % | ||||
| NON-GAAP ADJUSTED EBITDA CALCULATION | ||||||||
| Non-cash compensation | 746 | 758 | ||||||
| Divestiture/acquisition-related (income) expenses | (235 | ) | — | |||||
| Acquisition-related fair value adjustments | 51 | 111 | ||||||
| Unrealized foreign currency translation loss (gain) | 1 | (24 | ) | |||||
| Separation related expenses | — | 40 | ||||||
| Non-GAAP Adjusted EBITDA | $ | (1,585 | ) | $ | 3,037 | |||
| Non-GAAP Adjusted EBITDA/Total Revenue | (7.6 | )% | 9.2 | % | ||||